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trials are expected to ﬁnd no difference between their study
arms and cannot claim to be “negative” but are more properly termed inconclusive. The Cook et al study lacked the
statistical power to provide substantive evidence against
mild to moderate effects of gabapentin; however, it does represent some level of evidence against large effects, which it
would have been more adequately powered to detect. Further studies of greater size are needed to conﬁrm or refute
the ﬁndings of our initial study of gabapentin’s effectiveness
in the head and neck cancer population.
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In Reply to Smith et al.

To the editor: We would like to sincerely thank Drs Smith
and Murphy for their careful and critical evaluation1 of our
recently published double-masked, randomized, placebocontrolled trial regarding the role of prophylactic gabapentin in alleviating mucositis-related pain in patients receiving
radiation therapy for oropharyngeal cancers.2
They have conducted a detailed statistical analysis to
conclude that approximately 190 patients, randomized
between 2 treatment arms, would be required to prove or
disprove the role of gabapentin. As per their evaluation, the
60 patients in our study are inadequate to conclude that this
is a “negative” trial. We completely agree with this statement
and, in fact, acknowledged this limitation in the Discussion
section of our published manuscript.
Disclosures: none.

We would again like to highlight some of the unique
strengths of our study. It is the only existing study which
was double-masked and placebo-controlled. All patients
had a diagnosis of oropharyngeal cancer and received radiation to a dose of 70 Gy in 35 fractions with intermediateand low-risk areas receiving 63 Gy and 56 Gy, respectively.
We used a simultaneous integrated boost technique delivered using volumetric modulated arc therapy. T- and Nstages were well balanced between the arms. All patients
received platinum-based radiosensitizing chemotherapy
concurrent with radiation. Analysis of oral cavity and pharyngeal constrictor mean dose showed no difference
between the 2 arms (Table 1 of the manuscript). This group
of patients was speciﬁcally chosen as treating oropharyngeal
cancers results in the inclusion of a signiﬁcant portion of
the oral mucosa. Analyzing patients with laryngeal/ hypopharyngeal cancers or those receiving adjuvant radiation
therapy for oral cavity cancers would have resulted in highly
variable doses of radiation therapy to the oral cavity. We
wanted to minimize heterogeneity in the patient population
enrolled in our trial. Our strategy contrasts with the Smith
et al study,3 which was not placebo-controlled and included
patients with different head and neck subsites, radiation
doses, use of induction chemotherapy and different chemotherapy or targeted agents which are also known to impact
oral mucositis. Between 20% to 25% of the patients received
postoperative radiation therapy. The inclusion of such a heterogenous group of patients can introduce variability and
serve as confounding factors. Again, we view our homogenous inclusion criteria as a strength.
Understandably, one of the downsides to having narrow inclusion criteria is that it takes a long time to
accrue subjects and complete a trial. Ours was a single
institution, single enrolling site trial, that took 3 1/2 years
(June 2017-December 2020) to enroll 60 patients with
oropharyngeal cancer. During this period, several new
and exciting treatment de-escalation trials were also
opened at our institution and patients were preferentially
offered enrollment on these cooperative group trials. A
successful trial with the number of patients recommended by Drs Smith and Murphy, to be appropriately
powered, would have likely taken us a decade or longer
to accomplish using our inclusion criteria.
An additional surprising ﬁnding in our trial was the
signiﬁcantly higher number of patients who required
placement of a feeding (Dobhoff nasogastric) tube in
the gabapentin arm. As this was a masked trial, investigators had no way of knowing which patients were
requiring feeding tubes while the trial was ongoing. At
our institution, we do not place prophylactic percutaneous endoscopic gastrostomy tubes. We have a reactive
feeding tube policy where all patients receiving radiation therapy are evaluated on a weekly basis by speechlanguage pathologists and cancer dietitians. When the
need for a feeding tube is deemed necessary, based on
multidisciplinary evaluation, a Dobhoff tube is placed
in the Radiation Oncology clinic by the treating head
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and neck radiation oncologist (F.S.) or the head and
neck team nurse practitioner.
The number of patients who required a feeding tube placement were 18 of 29 in the gabapentin arm and 6 of 29 in the
control arm. As mentioned in our manuscript, 23 of these
(96%) were Dobhoff tubes and only 1 patient received a percutaneous endoscopic gastrostomy tube. Thus, although we
were unaware of this during the trial, in retrospect, it appears
that patients receiving gabapentin require feeding tubes at a
much higher rate. The exact cause of this is not clear to us.
These ﬁndings, along with a lack of clear and unequivocal beneﬁt in minimizing neuropathic pain resulting from
oral mucositis, has resulted in the discontinuation of prophylactic gabapentin for patients receiving head and neck
RT in our institution.
We deﬁnitely agree with the sentiment that further
large scale, adequately statistically powered double-masked
placebo-controlled trials should be conducted to answer this
question.
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